Tveito, Marit http://orcid.org/0000-0003-3963-4759
Molden, Espen
Høiseth, Gudrun
Correll, Christoph U.
Smith, Robert Løvsletten
Funding for this research was provided by:
South-Eastern Norway Regional Health Authority (2017085)
South-Eastern Norway Regional Health Authority (2016097)
Article History
Received: 19 May 2019
Accepted: 20 September 2019
First Online: 21 October 2019
Compliance with ethical standards
:
: Dr. Correll has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gerson Lehrman Group, Indivior, Intra-Cellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. Prof. Molden has received speaker´s honoraria from Lundbeck and Lilly. The other authors have no conflicts of interest to declare.